Absci Prices $100M Offering; Interim ABS-201 Trial Shows 65-Day Half-Life
ABSI•Absci raised $100 million by selling 13.5 million shares at $7.41 each to fund ABS-201 development in androgenetic alopecia and endometriosis. Interim Phase 1 results show ABS-201 was well tolerated with no serious adverse events and at least a 65-day half-life, supporting ongoing multiple ascending dose studies.
1. Financing and Strategic Investor Participation
Absci sold 13,495,277 common shares at $7.41 per share in an underwritten offering, raising approximately $100 million before underwriting discounts and commissions. Strategic and financial investors including Eli Lilly, Adage, BVF Partners, Columbia Threadneedle, Invus, and Redmile participated, with net proceeds designated for ABS-201 advancement and general corporate purposes.
2. Interim Phase 1 ABS-201 Data and Trial Progress
Interim data from the HEADLINE Phase 1 trial demonstrated that single ascending IV doses of ABS-201 (150–1800 mg) were well tolerated with no serious adverse events and only mild treatment-emergent events. Pharmacokinetic analysis estimates a half-life of at least 65 days, supporting two to three injections over six months, and the study has moved into subcutaneous multiple ascending dose cohorts in androgenetic alopecia participants.
